Download PDF
Aktuelle Urol 2003; 34(5): 319-327
DOI: 10.1055/s-2003-42008
Übersichtsarbeit
© Georg Thieme Verlag Stuttgart · New York

Perioperative Immunmodulation beim Nierenzellkarzinom - eine Standortbestimmung

Perioperative Immune Modulation in Renal Cell Carcinoma - Review of the Current SituationM.  Böhm1 , T.  Klatte1 , E.  P.  Allhoff1
  • 1Urologische Klinik, Otto-von-Guericke Universität, Leipziger Str. 44, 39120 Magdeburg
Further Information

Publication History

Publication Date:
11 September 2003 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die wesentlichen Therapieoptionen beim Nierenzellkarzinom sind Chirurgie und Immuntherapie. Die Chirurgie geht allerdings mit einer erheblichen perioperativen Immundysfunktion einher. Diese Immundysfunktion kann durch eine Vorbehandlung mit Interleukin-2 (IL-2) moduliert werden, was das tumorspezifische Überleben zu verbessern scheint. Die perioperative Immunmodulation könnte die therapeutische Lücke zwischen neoadjuvanter und adjuvanter Immuntherapie schließen. In diesem Artikel wird die verfügbare Literatur kritisch gesichtet und eigene Originaldaten an 63 Patienten präsentiert.

Abstract

Surgery and immunotherapy are the mainstay in the treatment of renal cell carcinoma. Surgery, however, is associated with considerable perioperative immunodysfunction. This immunodysfunction can be modulated by pretreatment with Interleukin-2 (IL-2), which appears to prolong tumour-specific survival. Perioperative immunomodulation could help close the therapeutic gap between neoadjuvant and adjuvant immunotherapy. This article reviews recent literature and presents original data of 63 patients.

Schlüsselwörter

Immunmodulation - perioperativ - Interleukin-2 - Nierentumor

Key words

Immunomodulation - perioperative - interleukin-2 - renal cancer

Literatur

  • 1 Hermanek P, Schrott K M. Evaluation of the new tumor, nodes and metastasis classification of renal cell carcinoma.  J Urol. 1990;  144 238-242
    PubMedGoogle Scholar
  • 2 Carl P, Klein U, Gebauer A, Schmiedt E. The value of lymphography for the TNM classification of renal carcinoma.  Eur Urol. 1977;  3 286-288
    PubMedGoogle Scholar
  • 3 Giuliani L, Giberti C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors.  J Urol. 1990;  143 468-474
    PubMedGoogle Scholar
  • 4 Sánchez de la Muela P, Zudaire J J, Robles J E, Rosell D, Aguera L, De Castro F, Isa W, Berián J M. Renal cell carcinoma: vena caval invasion and prognostic factors.  Eur Urol. 1991;  19 284-290
    PubMedGoogle Scholar
  • 5 Herrlinger A, Schrott K M, Schott G, Sigel A. What are the benefits of extended dissection of the regional lymph nodes in the therapy of renal cell carcinoma?.  J Urol. 1991;  146 1224-1227
    PubMedGoogle Scholar
  • 6 Eschwege P, Saussine C, Steichen G, Delepaul B, Drelon L, Jacqmin D. Radical nephrectomy for renal cell carcinoma 30 mm or less: long-term follow results.  J Urol. 1996;  155 1196-1199
    PubMedGoogle Scholar
  • 7 Takashi M, Takagi Y, Sakata T, Shimoji T, Miyake K. Clinicopathological characteristics of small renal cell carcinomas.  Int Urol Nephrol. 1994;  26 621-629
    PubMedGoogle Scholar
  • 8 Siminovitch J P, Montie J E, Straffon R A. Lymphadenectomy in renal adenocarcinoma.  J Urol. 1982;  127 1090-1091
    PubMedGoogle Scholar
  • 9 Hultén L, Rosencrantz M, Seeman T, Wahlqvist L, Åhrén C. Occurrence and localization of lymph node metastases in renal carcinoma.  Scand J Urol Nephrol. 1969;  3 129-133
    PubMedGoogle Scholar
  • 10 Robson C J, Churchill B M, Anderson W. The results of radical nephrectomy for renal cell carcinoma.  J Urol. 1969;  101 297-301
    PubMedGoogle Scholar
  • 11 Parry-Billings M, Baigrie R J, Lamont P M, Morris P J, Newsholme E A. Effects of major and minor surgery on plasma glutamine and cytokine levels.  Arch Surg. 1992;  127 1237-1240
    PubMedGoogle Scholar
  • 12 Hensler T, Hecker H, Heeg K, Heidecke C-D, Bartels H, Barthlen W, Wagner H, Siewert J R, Holzmann B. Distinct mechanisms of immunosuppression as a consequence of major surgery.  Infect Immun. 1997;  65 2283-2291
    PubMedGoogle Scholar
  • 13 Allendorf J D, Bessler M, Whelan R L, Trokel M, Laird D A, Terry M B, Treat M R. Postoperative immune function varies inversely with the degree of surgical trauma in a murine model.  Surg Endosc. 1997;  11 427-430
    CrossrefPubMedGoogle Scholar
  • 14 Kuntz C, Wunsch A, Bay F, Windeler J, Glaser F, Herfarth C. Prospective randomized study of stress and immune response after laparoscopic vs. conventional colonic resection.  Surg Endosc. 1998;  12 963-967
    CrossrefPubMedGoogle Scholar
  • 15 Gitzelmann C A, Mendoza-Sagaon M, Talamini M A, Ahmad S A, Pegoli W J, Paidas C N. Cell-mediated immune response is better preserved by laparoscopy than laparotomy.  Surgery. 2000;  127 65-71
    CrossrefPubMedGoogle Scholar
  • 16 Ogawa K, Hirai M, Katsube T, Murayama M, Hamaguchi K, Shimakawa T, Naritake Y, Hosokawa T, Kajiwara T. Suppression of cellular immunity by surgical stress.  Surgery. 2000;  127 329-336
    CrossrefPubMedGoogle Scholar
  • 17 Leaver H A, Craig S R, Yap P L, Walker W S. Lymphocyte responses following open and minimally invasive thoracic surgery.  Eur J Clin Invest. 2000;  30 230-238
    CrossrefPubMedGoogle Scholar
  • 18 Böhm M, Ittenson A, Philipp C, Röhl F-W, Ansorge S, Allhoff E P. Complex perioperative immunodysfunction in patients with renal cell carcinoma.  J Urol. 2001;  166 831-836
    PubMedGoogle Scholar
  • 19 Ashida S, Okuda H, Chikazawa M, Tanimura M, Sugita O, Yamamoto Y, Nakamura S, Moriyama M, Shuin T. Detection of circulating cancer cells with von Hippel-Lindau gene mutation in peripheral blood of patients with renal cell carcinoma.  Clin Cancer Res. 2000;  6 3817-3822
    PubMedGoogle Scholar
  • 20 McKiernan J M, Buttyan R, Bander N H, de-la-Taille A, Stifelman M D, Emanuel E R, Bagiella E, Rubin M A, Katz A E, Olsson C A, Sawczuk I S. The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9.  Cancer. 1999;  86 492-497
    CrossrefPubMedGoogle Scholar
  • 21 Bilkenroth U, Taubert H, Riemann D, Rebmann U, Heynemann H, Meye A. Detection and enrichment of disseminated renal carcinoma cells from peripheral blood by immunogenetic cell separation.  Int J Cancer. 2001;  92 577-582
    CrossrefPubMedGoogle Scholar
  • 22 Thèze J. The cytokine network and immune functions. New York: Oxford University Press 1999
    Google Scholar
  • 23 Mocellin S, Wang E, Marincola F M. Cytokines and immune response in the tumor microenvironment.  J Immunther. 2001;  24 392-407
    PubMedGoogle Scholar
  • 24 Abbas A K, Lichtman A H, Pober J S. Cellular and molecular immunology. Philadelphia: Saunders 2000
    Google Scholar
  • 25 Smith K A. IL-2. In: Oppenheim JJ, Feldman M (Hrsg.). Cytokine reference. London: Academic Press 2001: 113-126
    Google Scholar
  • 26 Civallero M, Barni S, Nano R, Capelli E. Dendritic cells and interleukin-2: cytochemical and ultrastructural study.  Histol Histopathol. 2000;  15 1077-1085
    PubMedGoogle Scholar
  • 27 Schnurr M, Galambos P, Scholz C, Dauer M, Krug A, Hartmann G, Eigler A, Endres S. Deutsches Ärzteblatt . 2002;  99 A2408-A2416
    PubMed
  • 28 Overwijk W W, Theoret M R, Restifo N P. The future of Interleukin-2: enhancing therapeutic anticancer vaccines.  Cancer J Sci AM. 2000;  6 Suppl 1 S76-S80
    PubMedGoogle Scholar
  • 29 Hoffman D M, Figlin R A. Intratumoral interleukin-2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex.  World J Urol. 2000;  18 152-156
    CrossrefPubMedGoogle Scholar
  • 30 Larchian W A, Horiguchi Y, Nair S K, Fair W R, Heston W D, Gilboa E. Effectiveness of combined Interleukin-2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer.  Clin Cancer Res. 2000;  6 2913-2920
    PubMedGoogle Scholar
  • 31 Dudley M E, Wunderlich J R, Robbins P F, Yang J C, Hwu P, Schwartzentruber D J, Topalian S L, Sherry R, Restifo N P, Hubicki A M, Robinson M R, Raffeld M, Duray P, Seipp C A, Rogers-Freezer L, Morton K E, Mavroukakis S A, White D E, Rosenberg S A. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes.  Science. 2002;  298 850-854
    CrossrefPubMedGoogle Scholar
  • 32 Holden S A, Lan Y, Pardo A M, Wesolowski J S, Gillies S D. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.  Clin Cancer Res. 2001;  7 2862-2869
    PubMedGoogle Scholar
  • 33 Nichols P H, Ramsden C W, Ward U, Sedman P C, Primrose J N. Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer.  Cancer Res. 1992;  52 5765-5769
    PubMedGoogle Scholar
  • 34 Nichols P H, Ramsden C W, Ward U, Trejdosiewicz L K, Ambrose N S, Primrose J N. Perioperative modulation of cellular immunity in patients with colorectal cancer.  Clin Exp Immunol. 1993;  94 4-10
    PubMedGoogle Scholar
  • 35 Deehan D J, Heys S D, Simpson W, Broom J, McMillan D N, Eremin O. Modulation of the cytokine and acute-phase response to major surgery by recombinant interleukin-2.  Br J Surg. 1995;  82 86-90
    PubMedGoogle Scholar
  • 36 Böhm M, Ittenson A, Schierbaum K F, Röhl F-W, Ansorge S, Allhoff E P. Petreatment with interleukin-2 (IL-2) attenuates perioperative immunodysfunction in patients with renal cell carcinoma.  Eur Urol. 2002;  41 458-468
    CrossrefPubMedGoogle Scholar
  • 37 Brivio F, Lissoni P, Alderi G, Barni S, Lavorato F, Fumagalli L. Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advances colorectal cancer patients.  Oncology. 1996;  53 263-268
    PubMedGoogle Scholar
  • 38 Brivio F, Brivio O, Lissoni P, Emanuelli G, Girlando M, Uggeri F. Presurgical neuroimmunotherapy with melatonin and interleukin-2 in cancer patients. In: Maestroni GJM, Conti A, Reiter RJ (Hrsg.). Therapeutic potential of melatonin. Front Horm Res. Basel: Karger 1997: 137-148
    Google Scholar
  • 39 Masotti A, Morandini G, Ortolani R, Fumagalli L. Phase-II randomized study of preoperative IL-2 administration in operable NSCLC.  Lung Cancer. 1998;  20 191-202
    CrossrefPubMedGoogle Scholar
  • 40 De Maeyer E, De Maeyer-Guignard J. Type I interferons. In: Bona CA, Revillard J-P (Hrsg.). Cytokines and cytokine receptors: physiology and pathological disorders. Amsterdam: Harwood Academic Publishers 2000: 316-333
    Google Scholar
  • 41 Luft T, Pang K C, Thomas E, Hertzog P, Hart D N, Trapani J, Cebon J. Type I IFNs enhance the terminal differentiation of dendritic cells.  J Immunol. 1998;  161 1947-1953
    PubMedGoogle Scholar
  • 42 Sedman P C, Ramsden C W, Brennan T G, Giles G R, Guillou P J. Effects of low dose perioperative interferon on the surgically induced suppression of antitumour immune responses.  Br J Surg. 1988;  75 976-981
    PubMedGoogle Scholar
  • 43 Fujioka T, Yoshida N, Hasegawa M, Ishikura K, Suzuki Y, Kubo T. Interleukin-2 expanded tumor-infiltrating lymphocytes and their response to preoperative α-interferon in patients with renal cell carcinoma.  J Urol. 1994;  152 852-856
    PubMedGoogle Scholar
  • 44 Houvenaeghel G, Bladou F, Blache J L, Olive D, Monges D, Jacquemier J, Chaudet H, Delpero J R, Guerinel G. Tolerance and feasibility of perioperative treatment with interferon-α2a in advanced cancers.  Int Surg. 1997;  82 165-169
    PubMedGoogle Scholar
  • 45 Sejima T, Miyagawa I. The evaluation of Fas/Fas ligand system in renal cell carcinoma - the effect of preoperative interferon-α therapy.  Nippon Hinyokika Gakkai Zasshi. 1999;  90 826-832
    PubMedGoogle Scholar
  • 46 Nielsen H J, Pedersen B K, Moesgaard F, Haahr P M, Kehlet H. Effect of ranitidine on postoperative suppression of natural killer cell activity and delayed hypersensitivity.  Acta Chir Scand. 1989;  155 377-382
    PubMedGoogle Scholar
  • 47 Katoh J, Tsuchiya K, Osawa H, Sato W, Matsumura G, Iida Y, Suzuki S, Hosaka S, Yoshii S, Tada Y. Cimetidine reduces impairment of cellular immunity after cardiac operations with cardiopulmonary bypass.  J Thorac Cardiovasc Surg. 1998;  116 312-318
    PubMedGoogle Scholar
  • 48 O'Riordain M G, Fearon K C, Ross J A, Rogers P, Falconer J S, Bartolo D C, Garden O J, Carter D C. Glutamine-supplemented total parenteral nutrition enhances T-lymphocyte response in surgical patients undergoing colorectal resection.  Ann Surg. 1994;  220 212-221
    PubMedGoogle Scholar
  • 49 Kerrebijn J D, Simons P J, Balm A J, Tas M, Knegt P P, de Vries N, Tan I B, Drexhage H A. Thymostimulin enhancement of T-cell infiltration into head and neck squamous cell carcinoma.  Head Neck. 1996;  18 335-342
    CrossrefPubMedGoogle Scholar
  • 50 Hamano K, Gohra H, Katoh T, Fujimura Y, Zempo N, Esato K. The preoperative administration of lentinan ameliorated the impairment of natural killer activity after cardiopulmonary bypass.  Int J Immunopharmacol. 1999;  21 531-540
    CrossrefPubMedGoogle Scholar
  • 51 Hubel K, Mansmann G, Schafer H, Oberhauser F, Diehl V, Engert A. Increase of antiinflammatory cytokines in patients with esophageal cancer after perioperative treatment with G-CSF.  Cytokine. 2000;  12 1797-1800
    CrossrefPubMedGoogle Scholar
  • 52 Bex A, Horenblas S, Meinhardt W, Verra N, de Gast G C. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ.  Eur Urol. 2002;  42 570-576
    CrossrefPubMedGoogle Scholar
  • 53 Morris K T, Johnson N, Homer L, Walts D. A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites.  Am J Surg. 2000;  179 407-411
    CrossrefPubMedGoogle Scholar
  • 54 Oz M C, Whitworth G C, Liu E H. Complementary medicine in the surgical wards.  JAMA. 1998;  279 710-711
    CrossrefPubMedGoogle Scholar
  • 55 Fair W R. Back to the future - the role of complementary medicine in urology.  J Urol. 1999;  162 411-420
    CrossrefPubMedGoogle Scholar
  • 56 Bruss K, Salter C, Galán E. American Cancer Society's guide to complementary and alternative cancer methods. Atlanta: American Cancer Society 2000
    Google Scholar

PD Dr. med. Malte Böhm

Urologische Klinik · Otto-von-Guericke Universität

Leipziger Str. 44

39120 Magdeburg

Phone: 0391-67-15036

Fax: 0391-67-15094

Email: malte.boehm@medizin.uni-magdeburg.de

      >